The U.S. Supreme Court sided with the FDA to uphold access to the abortion pill mifepristone, preventing potential challenges to FDA approvals and raising concerns about overturning other drug approvals.
The Supreme Court's ruling supported the FDA's actions in modifying mifepristone's conditions of use, which allowed non-physician prescribers and distant access during the pandemic, signaling a positive shift in healthcare regulations.
Justice Brett Kavanaugh, in the majority opinion, highlighted that the plaintiff had no legal standing to contest the FDA's regulation of mifepristone, emphasizing the jurisdiction of federal courts in addressing such concerns.
#us-supreme-court #fda-regulation #abortion-pill-mifepristone #healthcare-regulations #legal-standing
[
add
]
[
|
|
...
]